HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety

Simon D Roger¹, Daniel W Coyne²

Affiliations

¹ Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia.
² Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.

PMID: 34535582
DOI: 10.1159/000518073

Free article

Comment

HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety

Simon D Roger et al. Am J Nephrol. 2021.

Free article

. 2021;52(10-11):894-898.

doi: 10.1159/000518073. Epub 2021 Sep 16.

Authors

Simon D Roger¹, Daniel W Coyne²

Affiliations

¹ Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia.
² Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.

PMID: 34535582
DOI: 10.1159/000518073

No abstract available

PubMed Disclaimer

Comment in

Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety".
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Yamamoto H, et al. Am J Nephrol. 2021;52(12):977-978. doi: 10.1159/000520156. Epub 2021 Nov 2. Am J Nephrol. 2021. PMID: 34727543 No abstract available.

Comment on

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Yamamoto H, et al. Am J Nephrol. 2021;52(10-11):884-893. doi: 10.1159/000518072. Epub 2021 Sep 16. Am J Nephrol. 2021. PMID: 34569482 Clinical Trial.
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Yamamoto H, et al. Am J Nephrol. 2021;52(10-11):871-883. doi: 10.1159/000518071. Epub 2021 Sep 16. Am J Nephrol. 2021. PMID: 34569489 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- S. Karger AG, Basel, Switzerland
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety

Affiliations

HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical